REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugsREGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugs

For research purposes only. Full disclaimer →

Research/New Clinical Trial Aims to Compare Peptide Therapy with Surgery for Obesity and Diabetes Management
Back to Research Library

New Clinical Trial Aims to Compare Peptide Therapy with Surgery for Obesity and Diabetes Management

May 25, 2026
Share
Emerging Research

Based on emerging research. These findings are promising but require further validation.

About This Analysis

This article is an AI-assisted summary of a recently published news item or clinical trial listing. It is intended to provide a quick, accessible overview for the peptide research community. For full accuracy, always refer to the original source linked below.

New Clinical Trial Aims to Compare Peptide Therapy with Surgery for Obesity and Diabetes Management

A groundbreaking new clinical trial has commenced to evaluate the effectiveness of a novel peptide therapy in managing obesity and type 2 diabetes. The study, titled "Side-to-Side Duodeno-Ileostomy Versus Semaglutide," is being conducted by GT Metabolic Solutions, Inc., and seeks to compare the efficacy of semaglutide with a surgical intervention known as side-to-side duodeno-ileostomy.

Background

The management of obesity and type 2 diabetes has seen significant advancements in recent years, particularly through the development of peptide therapies. Peptides are small chains of amino acids that play critical roles in numerous biological processes, including metabolism and appetite regulation. Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is one such therapy that has gained widespread recognition for its efficacy in weight loss and glycemic control.

In parallel with pharmacological advancements, surgical interventions have also shown promise in treating these conditions. One such intervention is the side-to-side duodeno-ileostomy, which aims to reroute food through the small intestine to reduce calorie absorption and promote weight loss.

Key Details

The clinical trial, currently recruiting participants via ClinicalTrials.gov (NCT07317115), will compare the long-term effects of semaglutide with those of side-to-side duodeno-ileostomy. The study aims to recruit adults who are living with obesity and type 2 diabetes and assess how each treatment modality affects body weight, glucose control, cardiovascular health, and quality of life.

Participants will be randomly assigned to either receive daily injections of semaglutide or undergo the surgical procedure. Both approaches have shown promise in previous studies, but this trial seeks to provide a more comprehensive comparison by examining outcomes over an extended period.

Key Takeaways

  • Peptide Therapy vs Surgery: The study compares the effectiveness of semaglutide—a peptide-based therapy—with side-to-side duodeno-ileostomy.
  • Patient Selection: Adults with obesity and type 2 diabetes are eligible to participate in the trial, providing valuable insights into these specific patient populations.
  • Long-term Outcomes: By tracking outcomes over an extended period, researchers aim to provide a more complete picture of each treatment's benefits and risks.
  • Regulatory Implications: The results could influence future FDA regulations concerning both pharmaceutical treatments and surgical interventions.

What This Means

For the peptide research community, this trial represents a significant step forward in understanding how non-invasive therapies like semaglutide stack up against more invasive options such as surgery. As researchers continue to explore new applications for peptides in metabolic disorders, studies like this one will be crucial in guiding clinical practice and regulatory decisions.

Moreover, the findings could have broader implications for healthcare providers and patients considering treatment options for obesity and type 2 diabetes. By providing a direct comparison between semaglutide and side-to-side duodeno-ileostomy, the study aims to empower individuals with more informed choices about their health management strategies.

---

Source: [ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07317115) — Published 2026-05-19

This article is for informational purposes only and does not constitute medical advice.

Editor's Note

This analysis was generated using AI tools and reviewed by the Peptide Contacts editorial team. While we strive for accuracy, AI-generated content may contain errors or omissions. We encourage readers to review the original source for complete details, methodology, and data.

Peptide Contacts provides curated research summaries for informational purposes only. This content does not constitute medical advice. Always consult a qualified healthcare provider before making any health decisions.

Comments

Sign in to join the discussion

This article was generated using AI and may contain inaccuracies. It is provided for informational purposes only and does not constitute medical advice. Always verify information with the original source and consult a qualified healthcare provider before making any health decisions.